US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

32.17

-0.6600-2.01%

Post-market: 31.74-0.4300-1.34%19:59 EDT

Volume:277.63K

Turnover:8.94M

Market Cap:1.54B

PE:-10.54

High:34.48

Open:33.33

Low:31.77

Close:32.83

52wk High:52.93

52wk Low:23.75

Shares:47.98M

Float Shares:30.39M

Volume Ratio:0.50

T/O Rate:0.91%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0525

EPS(LYR):-2.8633

ROE:-39.96%

ROA:-25.78%

PB:3.65

PE(LYR):-11.24

Loading ...

Overview Company News Filings

Rapport Therapeutics assumed with a Buy at Truist

Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading

Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile

Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market

Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)

Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million

Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics announces annual shareholder meeting

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million

Rapport CDO Krishnaswamy sells 20,225 shares for $808,844

Rapport Therapeutics presents results from Phase 2a trial of RAP-219

Rapport Therapeutics Inc: Rap-219 Was Generally Well Tolerated Throughout Treatment and Follow-up Periods

THOMSON REUTERS

Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures

Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares

Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/RAPP/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":32.17,"timestamp":1790971200000,"preClose":32.83,"halted":0,"volume":277626,"hourTrading":{"tag":"盘后","latestPrice":31.74,"preClose":32.17,"latestTime":"19:59 EDT","volume":8065,"amount":259147.3,"timestamp":1790985592488,"change":-0.43,"changeRate":-0.013366,"amplitude":0.017408},"delay":0,"changeRate":-0.020103563813585034,"floatShares":30393800,"shares":47978286,"eps":-3.052456,"marketStatus":"Market Closed","change":-0.66,"latestTime":"10-02 16:00:00 EDT","open":33.33,"high":34.48,"low":31.77,"amount":8944912.050288,"amplitude":0.082546,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.052456,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":32.83,"preHourTrading":{"tag":"盘前","latestPrice":33.37,"preClose":32.83,"latestTime":"04:01 EDT","volume":6,"amount":196.64570400000002,"timestamp":1790928062864,"change":0.54,"changeRate":0.016448,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":31.74,"preClose":32.17,"latestTime":"19:59 EDT","volume":8065,"amount":259147.3,"timestamp":1790985592488,"change":-0.43,"changeRate":-0.013366,"amplitude":0.017408},"volumeRatio":0.49592578678816457,"impliedVol":1.4481,"impliedVolPercentile":0.9482},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":30393800,"roa":"-25.78%","roe":"-39.96%","lyrEps":-2.863342,"volumeRatio":0.49592578678816457,"shares":47978286,"dividePrice":0,"high":34.48,"amplitude":0.082546,"preClose":32.83,"low":31.77,"week52Low":23.75,"pbRate":"3.65","psRate":"77.17","week52High":52.93,"institutionHeld":0,"latestPrice":32.17,"eps":-3.052456,"divideRate":0,"volume":277626,"delay":0,"ttmEps":-3.052456,"open":33.33,"prevYearClose":30.34,"prevWeekClose":33.91,"prevMonthClose":33.6,"prevQuarterClose":33.6,"fiveDayClose":33.91,"twentyDayClose":47.65,"sixtyDayClose":42.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"RAPP","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2026-05-07","symbol":"RAPP","fiscalQuarterEnding":"2026/03","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.42},{"market":"US","date":"2026-03-10","symbol":"RAPP","fiscalQuarterEnding":"2025/12","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"RAPP","fiscalQuarterEnding":"2025/09","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4615,"buy":0.5385,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1785211200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2026-10-02","current":-10.539054,"percent":0.627148,"low":-19.654107,"twenty":-15.71898,"median":-12.913036,"eighty":-6.468149,"high":-3.640031,"avg":-11.823269,"sd":4.348231,"marketCap":1575127129},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-17","current":-12.986138,"twenty":-13.856058,"median":-9.228454,"eighty":-5.262092,"marketCap":1146831851},{"date":"2025-10-24","current":-13.675391,"twenty":-13.856058,"median":-9.397898,"eighty":-5.294604,"marketCap":1207701093},{"date":"2025-10-31","current":-14.035682,"twenty":-13.934383,"median":-9.502263,"eighty":-5.303959,"marketCap":1239519106},{"date":"2025-11-07","current":-11.969573,"twenty":-13.970933,"median":-9.588184,"eighty":-5.319746,"marketCap":1169427252},{"date":"2025-11-14","current":-12.034803,"twenty":-13.934383,"median":-9.698265,"eighty":-5.33408,"marketCap":1175800274},{"date":"2025-11-21","current":-13.098276,"twenty":-13.915585,"median":-9.917175,"eighty":-5.342242,"marketCap":1279701555},{"date":"2025-11-28","current":-14.493474,"twenty":-13.931568,"median":-10.309179,"eighty":-5.356195,"marketCap":1416012409},{"date":"2025-12-05","current":-14.000764,"twenty":-13.954437,"median":-10.426271,"eighty":-5.376155,"marketCap":1367874660},{"date":"2025-12-12","current":-14.039791,"twenty":-13.99491,"median":-10.604143,"eighty":-5.393122,"marketCap":1371687551},{"date":"2025-12-19","current":-14.459326,"twenty":-14.050476,"median":-10.719003,"eighty":-5.431972,"marketCap":1412676130},{"date":"2025-12-26","current":-15.088628,"twenty":-14.119227,"median":-10.841851,"eighty":-5.476848,"marketCap":1474158998},{"date":"2026-01-02","current":-14.800808,"twenty":-14.281097,"median":-10.940782,"eighty":-5.513507,"marketCap":1446038926},{"date":"2026-01-09","current":-13.81051,"twenty":-14.281097,"median":-10.976093,"eighty":-5.513507,"marketCap":1349286816},{"date":"2026-01-16","current":-13.103154,"twenty":-14.237527,"median":-11.048158,"eighty":-5.513507,"marketCap":1280178166},{"date":"2026-01-23","current":-13.620256,"twenty":-14.172521,"median":-11.156822,"eighty":-5.535473,"marketCap":1330698972},{"date":"2026-01-30","current":-13.049493,"twenty":-14.13499,"median":-11.312246,"eighty":-5.592253,"marketCap":1274935441},{"date":"2026-02-06","current":-12.464095,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"marketCap":1217742075},{"date":"2026-02-13","current":-13.644647,"twenty":-14.087483,"median":-11.410917,"eighty":-5.641114,"marketCap":1333082029},{"date":"2026-02-20","current":-14.630067,"twenty":-14.14031,"median":-11.45735,"eighty":-5.660027,"marketCap":1429357528},{"date":"2026-02-27","current":-14.391029,"twenty":-14.240388,"median":-11.53826,"eighty":-5.735139,"marketCap":1406003571},{"date":"2026-03-06","current":-14.464204,"twenty":-14.259247,"median":-11.689515,"eighty":-5.790087,"marketCap":1413152741},{"date":"2026-03-13","current":-12.292686,"twenty":-14.284564,"median":-11.721364,"eighty":-5.811144,"marketCap":1370425569},{"date":"2026-03-20","current":-11.773881,"twenty":-14.259247,"median":-11.747556,"eighty":-5.859217,"marketCap":1312587588},{"date":"2026-03-27","current":-12.434179,"twenty":-14.240388,"median":-11.754185,"eighty":-5.89508,"marketCap":1386199565},{"date":"2026-04-02","current":-13.578981,"twenty":-14.21307,"median":-11.781033,"eighty":-5.908305,"marketCap":1513825524},{"date":"2026-04-10","current":-14.672331,"twenty":-14.286297,"median":-11.799793,"eighty":-5.924837,"marketCap":1635715486},{"date":"2026-04-17","current":-16.95336,"twenty":-14.342463,"median":-11.834618,"eighty":-5.953085,"marketCap":1890011406},{"date":"2026-04-24","current":-15.589888,"twenty":-14.384981,"median":-11.842483,"eighty":-5.987204,"marketCap":1738007454},{"date":"2026-05-01","current":-14.207247,"twenty":-14.395165,"median":-11.879676,"eighty":-6.003597,"marketCap":1583866549},{"date":"2026-05-08","current":-17.794666,"twenty":-14.442977,"median":-11.889648,"eighty":-6.018516,"marketCap":1908958386},{"date":"2026-05-15","current":-16.919116,"twenty":-14.478378,"median":-11.936812,"eighty":-6.027747,"marketCap":1815031955},{"date":"2026-05-22","current":-16.361832,"twenty":-14.513564,"median":-11.969573,"eighty":-6.033101,"marketCap":1755248294},{"date":"2026-05-29","current":-17.605688,"twenty":-14.602401,"median":-12.072587,"eighty":-6.039697,"marketCap":1888685426},{"date":"2026-06-05","current":-16.714035,"twenty":-14.636423,"median":-12.104204,"eighty":-6.052541,"marketCap":1793031568},{"date":"2026-06-12","current":-15.697551,"twenty":-14.689254,"median":-12.211886,"eighty":-6.082711,"marketCap":1683986170},{"date":"2026-06-18","current":-16.437623,"twenty":-14.725074,"median":-12.249449,"eighty":-6.104202,"marketCap":1763378872},{"date":"2026-06-26","current":-17.347109,"twenty":-14.756903,"median":-12.285702,"eighty":-6.170327,"marketCap":1860945807},{"date":"2026-07-02","current":-17.561106,"twenty":-14.865035,"median":-12.307654,"eighty":-6.173633,"marketCap":1883902733},{"date":"2026-07-10","current":-18.747004,"twenty":-14.94702,"median":-12.322165,"eighty":-6.184379,"marketCap":2011122364},{"date":"2026-07-17","current":-17.891017,"twenty":-15.011798,"median":-12.351888,"eighty":-6.210003,"marketCap":1919294660},{"date":"2026-07-24","current":-18.4483,"twenty":-15.085362,"median":-12.382727,"eighty":-6.318283,"marketCap":1979078322},{"date":"2026-07-31","current":-19.072457,"twenty":-15.112377,"median":-12.415031,"eighty":-6.358759,"marketCap":2046036022},{"date":"2026-08-07","current":-16.213135,"twenty":-15.201543,"median":-12.451899,"eighty":-6.368734,"marketCap":2223793556},{"date":"2026-08-14","current":-16.566431,"twenty":-15.503178,"median":-12.623979,"eighty":-6.396893,"marketCap":2272251624},{"date":"2026-08-21","current":-16.737832,"twenty":-15.582924,"median":-12.704769,"eighty":-6.419712,"marketCap":2295760985},{"date":"2026-08-28","current":-17.780229,"twenty":-15.689526,"median":-12.798103,"eighty":-6.426595,"marketCap":2438736277},{"date":"2026-09-04","current":-16.667872,"twenty":-15.740131,"median":-12.897046,"eighty":-6.440085,"marketCap":2286165327},{"date":"2026-09-11","current":-15.202219,"twenty":-15.758139,"median":-12.908089,"eighty":-6.450467,"marketCap":2085136309},{"date":"2026-09-18","current":-14.674024,"twenty":-15.740219,"median":-12.981196,"eighty":-6.457364,"marketCap":2012689097},{"date":"2026-09-25","current":-11.833664,"twenty":-15.737279,"median":-12.983667,"eighty":-6.460419,"marketCap":1623105415},{"date":"2026-10-02","current":-11.483866,"twenty":-15.71898,"median":-12.913036,"eighty":-6.468149,"marketCap":1575127129}],"updateTime":1791057662797},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636138002","title":"Rapport Therapeutics assumed with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2636138002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636138002?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:00","pubTimestamp":1779145236,"startTime":"0","endTime":"0","summary":"Truist assumed coverage of Rapport Therapeutics (RAPP) with a Buy rating with a price target of $56, up from $44. The firm’s thesis is largely cons...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assumed-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assumed-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635480754","title":"Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635480754","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635480754?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:07","pubTimestamp":1778713631,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V sold 133,618 shares of Rapport Therapeutics common stock on May 11, 2026.Sale priced at weighted average USD 40.24 per share.Third Rock Ventures V held 6,299,097 shares following transaction.Separate Third Rock Ventures VI stake reported at 969,218 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2qDBmD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634925871","title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77","url":"https://stock-news.laohu8.com/highlight/detail?id=2634925871","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634925871?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:07","pubTimestamp":1778533675,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics , sold 276,513 common shares on May 7-8.Sales priced at USD 40.12 per share on May 7, USD 40.31 per share on May 8.Direct holdings fell to 6,432,715 shares following transactions.Separate indirect stake of 969,218 shares reported as held by Third Rock Ventures VI, L.P.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL5GLbNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633372834","title":"Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2633372834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633372834?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:45","pubTimestamp":1778237100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 06:45 ET (10:45 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633317267","title":"Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2633317267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633317267?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:36","pubTimestamp":1778186189,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Rapport Therapeutics, Inc. today and set a price target of $50.00. According to TipRan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120718","title":"Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120718?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:06","pubTimestamp":1778177171,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating on April 22. Joseph Thome has given his Buy ra...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rap-219-developer-as-accelerating-clinical-milestones-and-multi-indication-potential-enhance-risk‑reward-profile-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rap-219-developer-as-accelerating-clinical-milestones-and-multi-indication-potential-enhance-risk‑reward-profile-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633305122","title":"Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2633305122","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633305122?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:31","pubTimestamp":1778171466,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ($RAPP) announced an update on their ongoing clinical study. Rapport Therapeutics Inc. (RAPP) has announced a new Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-advances-rap-219-into-phase-3-setting-up-new-catalyst-in-focal-seizure-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-advances-rap-219-into-phase-3-setting-up-new-catalyst-in-focal-seizure-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126577","title":"Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633126577?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:35","pubTimestamp":1778164553,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $20,000, consensus $6M. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-reports-q1-eps-42c-consensus-71c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-reports-q1-eps-42c-consensus-71c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633495841","title":"Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633495841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633495841?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:31","pubTimestamp":1778153486,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryRapport Therapeutics Inc RAPP.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459211","title":"Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459211?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:03","pubTimestamp":1778151822,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics posted a Q1 net loss of USD 19.9 million, narrowing from USD 24.1 million a year earlier, while loss per share improved to USD 0.42 from USD 0.68.Collaboration revenue was USD 20 million versus no revenue a year earlier, while R&D expense rose to USD 32.7 million from USD 19.6 million.G&A expense climbed to USD 11.5 million from USD 7.5 million; cash, cash equivalents and short-term investments ended at USD 476.8 million, down from USD 490.5 million at year-end.Phase 2a follow-up data for RAP-219 in focal onset seizures showed a 90% median reduction in clinical seizures over baseline in weeks 9-12; RAP-219 half-life estimate was raised to 22 days from 14 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1t8R84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633814551","title":"Press Release: Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633814551","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633814551?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:00","pubTimestamp":1778151600,"startTime":"0","endTime":"0","summary":"Phase 2a follow-up period data for RAP-219 in focal onset seizures  demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12. RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance. Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and <ALPHA>6<BETA>4 nAChR in chronic pain and migraine, continue to advance. Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications. \"We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,\" said Abraham N. Cees","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","RAPP","BK4181","PK","BK4007","AAN","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835569","title":"Rapport Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835569","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835569?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:22","pubTimestamp":1776943333,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics scheduled 2026 annual shareholder meeting for June 10, 2026 in virtual format.Shareholders will vote to elect Class II directors James Healy, Robert Perez, Raymond Sanchez to terms running to 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL8rpgJj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629884497","title":"Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2629884497","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629884497?lang=en_us&edition=fundamental","pubTime":"2026-04-23 17:42","pubTimestamp":1776937320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 05:42 ET (09:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706901","title":"Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706901","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706901?lang=en_us&edition=fundamental","pubTime":"2026-04-22 07:36","pubTimestamp":1776814611,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V sold 426,005 shares of Rapport Therapeutics common stock on April 17.Sale priced at weighted average USD 40.32 per share.Third Rock Ventures V held 6,709,228 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL2SNvVT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Third Rock Ventures V disposes of Rapport Therapeutics shares worth $17.2 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629206388","title":"Rapport CDO Krishnaswamy sells 20,225 shares for $808,844","url":"https://stock-news.laohu8.com/highlight/detail?id=2629206388","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629206388?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:55","pubTimestamp":1776804939,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 20,225 common shares on April 17, 2026.Sale price was USD 39.99 per share on a weighted-average basis.Trade was executed under a Rule 10b5-1 plan adopted Dec. 10, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDLcdrNTm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport CDO Krishnaswamy sells 20,225 shares for $808,844","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629068134","title":"Rapport Therapeutics presents results from Phase 2a trial of RAP-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2629068134","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629068134?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:39","pubTimestamp":1776803943,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures, FOS, in a late-br...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-presents-results-from-phase-2a-trial-of-rap-219-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-presents-results-from-phase-2a-trial-of-rap-219-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629068520","title":"Rapport Therapeutics Inc: Rap-219 Was Generally Well Tolerated Throughout Treatment and Follow-up Periods","url":"https://stock-news.laohu8.com/highlight/detail?id=2629068520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629068520?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:36","pubTimestamp":1776803789,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nFWN4140LX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629556068","title":"Rapport Therapeutics says RAP-219 Phase 2a follow-up sustains seizure reductions in focal seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2629556068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629556068?lang=en_us&edition=fundamental","pubTime":"2026-04-22 04:32","pubTimestamp":1776803570,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics presented follow-up results from Phase 2a trial of RAP-219 in focal onset seizures at 2026 American Academy of Neurology Annual Meeting on April 21, 2026.Data showed seizure control remained durable beyond end of dosing, with clinical outcomes holding up through 16 weeks of drug exposure.Pharmacokinetic analyses supported a longer drug persistence than previously estimated, reinforcing rationale for less frequent dosing.Safety profile remained broadly consistent through follow-up, with no new treatment-related serious safety signals reported.Company plans to start two pivotal Phase 3 trials in focal onset seizures in Q2 2026, with initial open-label long-term safety data expected in 2H 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL8q46F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014021.USD","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","BK4112","NDAQ","IE00BN0W2V16.EUR","BK4007","BK4588","RAPP","SG9999014005.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627421941","title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627421941","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627421941?lang=en_us&edition=fundamental","pubTime":"2026-04-15 04:14","pubTimestamp":1776197669,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 19,865 shares in transactions dated April 10 to April 14.Sales prices ranged from USD 34.97 to USD 35.08 per share.Krishnaswamy’s direct holding fell to 266,651 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 14, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL7rR8C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells USD 696,440 shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626213075","title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2626213075","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626213075?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:31","pubTimestamp":1775766713,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 360 shares on April 8, 2026 at USD 34.9 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4PTT8y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Rapport Therapeutics Chief Development Officer Krishnaswamy sells $12,564 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":81,"code":"91000000","status":"200"}]}}